Postural Hypotension and LHRH Agonists/Antagonists
Medical castration with LHRH agonists or antagonists does NOT cause postural (orthostatic) hypotension as a recognized adverse effect in men with prostate cancer.
Evidence from Guidelines
The NCCN guidelines and ASCO recommendations comprehensively detail the adverse effects of androgen deprivation therapy (ADT) with LHRH agonists and antagonists, but postural hypotension is notably absent from these lists 1, 2.
Well-Documented Side Effects of ADT
The established adverse effects that clinicians should monitor include 2:
- Metabolic complications: Osteoporosis, clinical fractures, obesity, insulin resistance, lipid alterations
- Cardiovascular risks: Increased risk for diabetes and cardiovascular disease
- Hormonal effects: Hot flashes, gynecomastia, fatigue, loss of libido, erectile dysfunction
- Cognitive/mood changes: Mental health alterations, lassitude
When abiraterone is added to ADT, specific cardiovascular monitoring is required for hypertension, hypokalemia, peripheral edema, atrial fibrillation, and congestive heart failure 1. However, even in this context where cardiovascular effects are prominent, orthostatic hypotension is not mentioned.
Mechanism Considerations
LHRH agonists and antagonists work by suppressing testosterone production through pituitary-gonadal axis modulation 3, 4, 5. The primary difference between them is that:
- LHRH agonists initially cause testosterone surge before downregulating receptors
- LHRH antagonists directly block receptors without initial surge
Neither mechanism involves blood pressure regulation pathways that would cause orthostatic hypotension 6, 5.
Clinical Implications
If a patient on LHRH therapy develops postural hypotension, look for alternative causes such as:
- Concurrent medications (antihypertensives, alpha-blockers for urinary symptoms)
- Dehydration
- Autonomic dysfunction from other conditions
- Age-related cardiovascular changes
The absence of postural hypotension from comprehensive guideline safety profiles across multiple iterations (2010-2025) 2, 7 and research reviews 3, 4, 5 strongly indicates this is not a treatment-related adverse effect requiring routine monitoring.